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Abstract
Visceral leishmaniasis (VL) is a disease caused by a protozoon belonging to the genus
Leishmania, and it is transmitted through the bite of sand flies. Endemic regions have
widened, and canine visceral leishmaniasis (CVL) occurs mainly in the Mediterranean
region and South America. There is no consensus on the risk factors associated with
CVL, as results differ between the studied regions and countries. This chapter describes
the main aspects of epidemiology, immunology, clinical signs, diagnosis treatment, and
control of canine visceral leishmaniasis with emphasis on Brazil.
Keywords: neglected diseases, risk factors, zoonosis
1. Introduction
Leishmaniases is  a  disease caused by protozoan intracellular  parasites  called Leishmania,
members of Trypanosomatidae family, and are endemics in 98 countries and territories.
More than 20 parasite species are involved in the three different clinical manifestation diseases
in human beings: cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis
(kala-azar). Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishma-
niasis in a patient who has recovered from the disease. The vectors are sand flies, insects of
medical and veterinary relevance, and different species involved in its transmission.
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According to Pan American Health Organization (PAHO) and World Health Organization
(WHO), there are more than 12 million people infected with leishmaniasis, and 350 million are
at risk in the world. Cutaneous leishmaniases are concentrated in ten countries, four of which
are in the Americas: Brazil, Colombia, Peru, and Nicaragua. Ninety percent of visceral
leishmaniasis cases occur in Brazil, Ethiopia, India, Bangladesh, Sudan, and South Sudan. In
the Americas, an average 60,000 cases of cutaneous and mucosal leishmaniasis and 4000 cases
of visceral leishmaniasis are diagnosed annually, with a fatality rate of 7% (Figure 1) [1].
Figure 1. High-burden countries for both visceral and cutaneous leishmaniasis [2].
The aim of this chapter is to describe the main aspects of canine visceral leishmaniasis (CVL)
with emphasis in Brazil.
2. Epidemiology
Visceral leishmaniasis (VL), also known as kala-azar, is a disease caused by an obligate
intracellular protozoon belonging to the family Trypanosomatidae, genus Leishmania. It is
transmitted through the bite of infected female sand flies and is widely distributed throughout
the world (Figure 2). Currently, the World Health Organization considers VL as a neglected
disease. An estimated 500,000 new cases of human VL occur per year [2]. Its epidemiology is
extremely complex and depends on social and environmental variables, the species of
Leishmania and the vector involved, and the behavior of reservoirs and hosts (Table 1).
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Figure 2. World distribution of human visceral leishmaniasis, 2013 [3].
Species Region Vector Host/reservoir
Leishmania (L.) infantum Old World:
Europe
Asia
Africa
Phlebotomus perniciosus
P. ariasi
Humans
Dogs
Wild canids
Leishmania (L.) donovani Old World:
Asia
Africa
P. argentipes
P. orientalis
Humans
Leishmania (L.) infantum (syn. of L. chagasi) New World:
South, Central, and North America
Lutzomyia longipalpis
Lu. cruzi
Lu. forattinii
Lu. evansi
Humans
Dogs
Wild canids
Felines
Marsupials
Adapted with permission from Refs. [4–6].
Table 1. Visceral leishmaniasis: species, region of occurrence, vectors, reservoirs, and mammal hosts.
2.1. Biological cycle
The life cycle of L. infantum is heteroxenic, that is, the parasite develops in two types of hosts:
in the intermediate host, or the vector, the promastigote form develops in the insect gut; once
in the definitive host, the amastigote develops as an obligate intracellular parasite in macro-
phages. During blood meals, vectors ingest macrophages containing Leishmania amastigotes,
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which will then multiply by binary division and differentiate into promastigotes. Promasti-
gotes bind to the epithelium of the sand fly’s esophagus or pharynx by the flagellum and then
differentiate into metacyclic promastigotes, which is the infectious stage, unable to divide or
bind to the midgut, remaining free in the digestive tract lumen [5, 7, 8].
Transmission occurs when the infected vector does a new blood meal and inoculates the
infective form of Leishmania in the host. The sand fly regurgitates around 1000 metacyclics into
the wound caused on the skin of a mammal [9]. When inoculated into the host organism, the
parasite is phagocytized by the cells of mononuclear phagocytic system and loses the flagella.
Next, it multiplies intensively by binary division, to the point of rupturing the host cell and
releasing amastigotes, which then will be phagocytized by other cells and spread via blood
and lymph to other tissues and organs [5, 7, 8].
2.2. Vector
VL vectors belong to the order Diptera, family Psychodidae, subfamily Phlebotominae, genus
Lutzomyia in the new world, and Phlebotomus in the Old World. They can be found in tropical
and subtropical regions of the planet and are popularly known as sand flies [10, 11].
Sand flies are small-sized, light brown-colored insects, with a coat of hair over their body. They
measure between 2 and 3 mm [11]. Their flight range reaches about 150–300 m (diameter of
300–600 m), but may be longer depending on the species. They usually fly in small jumps and
have crepuscular and nocturnal activity [12].
Hematophagy is a unique habit of females, who require blood for ovary maturation. Hence,
they are able to transmit the disease. When females feed on blood, they hold their wings
upright. A variety of animals has been identified as dietary hosts of sand flies, which have very
eclectic feeding habits. Females lay eggs in moist soil, rich in organic matter [13].
2.3. Transmission
VL caused by L. infantum is a zoonosis and can display either wild or domestic transmission
cycles depending on the eco-epidemiological conditions.
Leishmaniasis starts from the wild cycle, involving reservoirs such as wild canids and
marsupials. As for the domestic cycle, the main reservoir is the domestic dog (Canis lupus
familiaris) [7]. The link between wild and domestic cycles occurs when humans install
dwellings on forest banks [14] and, most likely, because some wild reservoirs have synan-
thropic habits (Figure 3) [15].
Canine visceral leishmaniasis (CVL) is crucial from an epidemiological point of view, as it is
more prevalent than human VL. Dogs exhibit high levels of subcutaneous parasites and high
sensitivity to vectorial infection [12]. Additionally, between 50 and 60% of infected animals are
asymptomatic [16]. It is estimated that three out of five asymptomatic positive dogs transmit
the parasite to sand flies, and this transmission rate does not significantly change among
symptomatic and asymptomatic groups of animals [17].
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Other animals have been pointed as possible reservoirs, such as rodents [14] and cats, or
accidental hosts, such as horses [18]. Adaptation of vectors to different animal species would
be a favorable factor for VL transmission [19].
Figure 3. Eco-epidemiology of visceral leishmaniasis in Pará, Brazil. L. infantum parasite is maintained by a sand fly
population (Lutzomyia longipalpis) and wild reservoirs (1). House invasion by sand flies near forests allows canine and
human infection (2 and 3), where domestic dogs become the main source of the parasite. The same occurs in the urban
areas. Solid lines indicate defined routes of transmission, and dashed lines represent possible transmission routes with
other wildlife, and possibly with man, serving as a source of infection for sand flies [14].
There are other transmission forms of less epidemiological importance, such as blood trans-
fusion and venereal transmission, apart from vertical transmission, which can be transplacen-
tal or transmammary [20–23]. Direct dog-to-dog transmission through bites or wounds has
been suggested as responsible for sporadic CVL transmission as well [24, 25].
2.4. Geographic distribution and prevalence
In recent years, endemic regions have widened, and there has been a sharp increase in number
of recorded cases of the disease. Still, it is believed that the impact of leishmaniasis on public
health has been underestimated, since its notification is only mandatory in 32 of the 88 affected
countries [2]. CVL is endemic in over 70 countries and occurs mainly in the Mediterranean
region and South America [26]. Moreno and Alvar concluded that at least 2.5 million dogs are
infected in only four countries in Southeastern portion of Western Europe, representing 16.7%
of the canine population [27].
Franco et al. [28] developed a database of publications on the prevalence of LVC in Europe
between the years 1971 and 2006. They found an overall prevalence of 23.2% and average
of 10%, the highest taking place in Italy (17.7%), followed by France (8%), Portugal (7.3%),
and Spain (5.9%) [28]. In another study, in 18 Portuguese cities with 3974 dogs, the overall
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prevalence of CVL was of 6.31% and ranged from 0.88% to 16.16% among cities, with high
prevalence in inland regions [29].
In Croatia, seroprevalence of CVL ranges from 0 to 42.85% depending on the studied region
[30]. In Cyprus, the seroprevalence of the disease in dogs had a ninefold increase compared to
10 years before, reaching 14.9% in 2010 [31]. The average seropositivity of dogs in Greece is
22.1%, and positive animals were found in 43 of 54 cities [32].
Seroprevalence of CVL in Southern Europe ranges from less than 5% to over 50% depending
on the geographic region [33]. However, the prevalence of infection is significantly higher than
both seroprevalence and apparent disease, due to sensitivity of serological techniques and
because clinical signs usually only appear in less than half of the population, as in all endemic
areas of the world [34].
Recent expansion to areas not previously endemic has been recorded in some parts of Europe,
as northern Italy [35], in Germany [36], and in northern Spain [37]. The expansion of the CVL
is associated with adjacent territories and often with global warming, which favors vector
transmission, or with import of infected dogs to non-endemic areas, such as the United
Kingdom and Poland [26, 33].
In Africa, VL transmission areas are located near forests [12]. Most of the information published
in Africa have often been reports of human cases during epidemic situations, but information
on the reservoirs are scarce [38]. In Algeria, the number of cases of CVL is on the rise, with a
frequency of 35%, with 25% of positive dogs being asymptomatic [39]. Coastal regions of
Northern Morocco are known to be endemic for canine and human VL. Moreover, several cases
of CVL caused by L. tropica have been reported in areas where it is normally caused by L.
infantum [40].
CVL exists in some Asian countries. It is endemic in Iran, with an average prevalence of 14.2%,
and variations according to the region: 18.2% in northeast, 12.3% in the central region, and
4.4% in Southeastern Iran [41]. Another study, restricted to southwestern Iran, found a
prevalence of 15.4% [42]. In China, VL is an anthropozoonosis which completes its life cycle
in dogs, raccoons, coatis, and children [12]. The presence of L. infantum DNA in dogs, in
Southwest China, ranged from 23.5 to 28.2% [43]. In the Western region, 51.9% of the dogs were
positive in PCR, but only 36.8% of the dogs reacted in serology [44].
CVL has been expanding over the Americas. It currently occurs from southern Canada [45]
and the United States [46, 47] to northern Argentina [48, 49]. In North America, it was first
reported on hunting kennels of Foxhound dogs in New York, in 1999 [46]. Since then, CVL has
been spreading and has so far been diagnosed in 18 North American and two Canadian states,
totaling 58 kennels with positive Foxhounds, but with no reports of human cases. Isozyme
characterization showed that the isolated agents from 46 Foxhounds are Leishmania infantum
(MON1) [45]. High mortality and transmissibility rates associate with these foci in North
America. It is believed that the disease was imported from Southern Europe due to dog travel
history between these regions [50]. Direct transmission forms are associated with these
outbreaks: from dog to dog, via placenta or during intercourse [22]. L. infantum, in these cases,
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remains capable of infecting sand flies and subsequently moving into a vertebrate host, which
highlights the risk of vector-based transmission to humans [47].
There are few studies on CVL in Mexico, but human VL cases are constant. Rosete-Ortíz et
al. analyzed skin lesions of 25 dogs by immunohistochemistry and PCR in a region where
Lutzomyia longipalpis has been described and found Leishmania sp. in 60% of samples [51].
In Latin America, VL occurs in 12 countries, with 90% of cases concentrated in Brazil [11],
distributed in all states of the Northeastern, Midwestern, and Southeastern regions, plus in
Roraima, Tocantins, and Pará states, in the Northern region [14]. Among Brazilian cities and
states, variation in prevalence of CVL is huge, ranging from 0.7% in Salvador, in the state of
Bahia [52], to 51.6% in São Luis Island, Maranhão state [53], both in Northeast, where the
disease is most prevalent.
CVL urbanization correlates with increasing global mobility [54] associated with demographic
and ecological factors. In Latin America, especially in Brazil, Colombia, and Venezuela,
migration and urbanization have contributed to the increase in American VL. In Brazil, one
example is the rural exodus from the Northeast fields, causing thousands of people to migrate
to cities like Fortaleza, Jacobina, João Pessoa, Natal, Petrolina, St. Louis, Sobral, Teresina, and
Salvador. They then proceed to live in suburban areas with unsanitary conditions and
malnutrition. Migrants often bring along their dogs and raise chicken and pigs around their
homes, all ultimately serving as a feed source for the vector. According to Moreno et al., in
urban areas, some factors favor the spread of L. infantum, such as the presence of waste and
degraded areas around houses, lack of vector recognition by locals, and increased exposure to
sand fly, especially in the early evening [55]. Thus, “ruralization” of the outskirts of the
Northeastern cities has been identified as the cause of epidemics detected in the region [56],
although this same process may not be necessary for entry of visceral leishmaniasis in other
cities, as happened in the Southeast of the country.
The state of Rio Grande do Sul, Brazil, was considered CVL-free until 2008, when a case of an
autochthonous canine was reported in São Borja [57]. In the same year, Lutzomyia longipalpis
was found in urban areas of San Borja, a species not previously reported in the Southern region
[58]. Since then, new cases were reported: 24 in dogs and 10 in humans between 2008 and 2014.
Of these 34 reports, 20 were autochthonous, showing that it is an emerging zoonosis in the
state [59]. It is believed that the disease has entered the state via Santo Tomé city in Argentina,
which borders San Borja and already had reports of the disease [57, 59].
Prevalence of CVL in the world varies widely, and such variation also applies to different
locations within the same city, suggesting that different ecosystems favor maintenance of
vectors in different manners [60]. As noted by Azevedo et al. [61] and Belo et al. [62], results
of studies on prevalence are influenced by various factors such as the region and population
studied, the diagnostic method, as well as the sample used.
Migration of humans and their pets, disorderly occupation, poor living conditions, defores-
tation, and climate change associated with vector-adaptive capacity are some of the causes of
the global urbanization of leishmaniasis [54].
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The best example of the phenomenon of urbanization of zoonotic visceral leishmaniasis is
happening in Brazil [54, 63]. VL has invaded urban centers and large capitals with no previous
record of autochthonous cases [12]. Epidemiological data show the suburbanization and
urbanization of visceral leishmaniasis, highlighting the outbreaks in Rio de Janeiro (RJ), Belo
Horizonte (MG), Aracatuba (SP), Santarém (PA), Corumbá (MS), Teresina (PI), Natal (RN), São
Luís (MA), Fortaleza (CE), Camaçari (BA), and more recently, occurrence of epidemics in the
municipalities of Três Lagoas (MS), Campo Grande (MS), and Palmas (TO) [11].
The prevalence of human VL caused by L. infantum has decreased where living standards
improved [2], showing that one of the most important interventions may be socioeconomic
development and improved nutrition of children [8], but CVL cases have increased.
2.5. Risk factors
There is no consensus on the risk factors associated with CVL, as results differ between the
studied Brazilian regions and between countries.
In Croatia, risk factors were sex (male), age (the two most prevalent groups comprise dogs
between 3 and 4 years old and between 6 and 7 years old), and location (dogs in some cities
are more likely to acquire the disease) [30]. In Spain, seroprevalence was also found to have
bimodal age distribution, but the age groups were between 1 and 2 years and between 7 and
8 years; infection is also related to outdoor rearing [64]. In Portugal, risk factors are outdoor
rearing, age (over two years), short fur, pure breeds, and location (dogs in the hinterlands are
more likely to be affected) [29].
In Brazil, Belo et al. [62] conducted a systematic review of the literature on risk factors
associated with CVL, and the variables that showed significant association with infection were
short hair, pure breed, rearing restricted to house surroundings, and the presence of green
areas adjacent to the house. The occurrence of CVL was also associated with the presence of
poultry in domestic environment, free-living dogs, sex (male), and age greater than 1 or 2 years,
although these associations were not statistically significant [62].
Another study in Brazil defined risk factors as outdoor rearing, contact with poultry, dogs
living in rural areas, the presence of organic matter, the absence of environmental management,
and proximity to forests [65]. As for dogs in the countryside, in an endemic area of Northeastern
Brazil, the only identified risk factor found was sex, as male dogs were twice as likely to develop
the disease [66].
3. Immunology
The components of the immune system act in a complex and coordinated manner to prevent
entry and survival of foreign agents in the body. The first line of defense is the innate immunity,
which responds immediately and unspecifically to a range of pathogens, and further presents
them to the constituents of adaptive immunity when needed. Adaptive immunity will then
generate a specific response and develop memory cells against such antigen. Performance of
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these defense mechanisms can control infection and ensure the least possible damage to host
tissues.
In visceral leishmaniasis, the result of the relationship between parasite and host is determined
by complex factors involving saliva components of the vector insect, agent-secreted surface
proteins, and different responses produced by the host [67]. Leishmaniasis can be considered
an immune-mediated disease, considering the parasite’s ability to alter the immune system
[68]. It ultimately promotes inhibition of immune response by either stimulating the develop-
ment of regulatory T cells [69] or exerting some degree of control over the complement system,
exploring its opsonic properties to facilitate adherence with phagocytic cells and preventing
their lytic effects through the action of gp63 glycoprotein expressed on the parasite surface [70].
Thus, infection outcome depends on the parasite’s capacity of developing evasion mechanisms
to escape from host responses and remain unharmed in the cytoplasm of phagocytic cells.
It has been documented that resistance to infection by L. infantum in dogs is characterized by
the absence of clinical signs, low levels of anti-Leishmania antibodies, in vitro lymphocyte
proliferative response, and delayed hypersensitivity response to skin antigens. Progression of
the infection, however, relates to exaggerated humoral response and cellular immune depres-
sion, consequently bringing up an onset of clinical signs [71–74]. Asymptomatic animals also
exhibit lower parasitism, whereas the symptomatic generally carry high parasite load in
different tissues such as the skin, bone marrow, spleen, liver, and lymph node [73–76].
3.1. Innate response
Through antigen presentation, the cells of innate immunity stimulate the acquired response.
Antigen-presenting cells have receptors that recognize pathogen-associated molecular
patterns (PAMPs) expressed by the parasite. Among these, the Toll-like receptor (TLR) is one
of the most studied. Stimulation of these receptors culminates with the activation of signaling
pathways in infected cells, which results in induction of antimicrobial genes and inflammatory
cytokines (IL-12, TNF) while increasing the ability of cells to present antigen. Thus, pathogen
recognition by TLR receptors helps conducting adaptive immune response against the
presented antigen [77].
Expression of TLR genes in dogs infected with L. infantum varies according to the different
tissues and stages of infection. As the disease progresses, there is a significant decrease in
transcription for TLR3, TLR4, TLR9, IL-17, IL-22, and FoxP3 in lymph nodes. In spleen samples,
decreased transcription for TLR4 and IL-22 has been observed when infected groups were
compared with controls. In the skin, upregulation was observed only for TLR9 and FoxP3 in
early stages of infection, as well as downregulation for TLR3 and TLR9 in later stages. Decrease
in transcription of TLRs, Th17, and FoxP3 cytokines is suggestive of silent establishment of
infection [78]. In peripheral blood samples from infected dogs, the highest expression of TLR2
and its receptor CD11b (CR3) by monocytes correlates with reduced parasitic load and higher
resistance to leishmaniasis [79].
Studies have shown that both inlet and survival of Leishmania spp. within macrophages can
occur from prior infection of neutrophils, which are recruited as a normal response to insect
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bites. The agent reaches the interior of macrophages when they phagocyte apoptotic bodies of
previously infected neutrophils, where it can survive and multiply. This parasite escape
mechanism is called “Trojan Horse” [80].
The main effector mechanism involved in protective immune response against Leishmania
spp. is the activation of macrophages by IFN-γ and tumor necrosis factor alpha (TNF-α)
stimulation, with consequent stimulation of nitric oxide synthesis, which is required for
effective destruction of the pathogen and for controlling the spread of infection in dogs [81–83].
3.2. Acquired response
3.2.1. Lymphocytes
The major subpopulations of lymphocytes are CD4+ T cells (Th1, producing IFN-γ and TNF-
α; Th2, secreting IL-4, IL-5, and IL-13; and Th17, producing IL-17 and IL-22) and CD8+ T cells.
Antigen-presenting cells submit Leishmania spp. antigens to CD4+ T cells via MHC class II, and
because the agent is an intracellular parasite, there may be presentation via MHC class I with
activation of CD8+ T cells as well [69].
The role of CD4+ T cells in the response to visceral leishmaniasis (VL) has not been fully
elucidated. Research carried out so far points to a mixed response (Th1/Th2) during infection
[84, 85]. It is reported, however, that control of infection depends on Th1 cells that activate
macrophages, promoting elimination of intracellular parasites [86], whereas Th2 cells direct
the immune system toward humoral response and negatively regulate cellular immunity,
promoting Th1 cell anergy [87].
CD8+ cells constitute a significant population in cellular immunity against canine visceral
leishmaniasis (CVL), outnumbering CD4+ cells in the dermis [87]. They play an important role
in resistance to infection. Guerra et al. [88] associated phenotypic changes with tissue parasit-
ism in the spleen and skin of infected dogs. They noticed that the high frequency of CD8+-
circulating lymphocytes is directly related to low splenic parasitism and that there is a negative
correlation between CD8+ T cells with skin parasite density, indicating that this cell type relates
to resistance against LVC [88].
The regulatory role of FOXP3+ CD4+ T cells in canine VL has not been fully elucidated;
however, reduction of Treg cell percentage in peripheral blood of infected dogs has been
observed [89]. Silva et al. [90] reported increased production of IL-10 by splenic Treg cells of
dogs with LV, along with decrease in the total number of T cells when compared to healthy
dogs. The findings suggest that Treg cells are a major source of IL-10 in the spleen and
participate in the modulation of immune response, while a small percentage of these cells in
infected dogs may be related to persistent immune activation [90].
T-cell exhaustion (CD4+ and CD8+ cells) in peripheral blood of dogs with LV, followed by
reduction of the expression of cytokines (such as IFN-γ), was recently demonstrated. This
phenomenon, called cell exhaustion, is mainly mediated by high expression of programmed
death protein (“programmed cell death 1,” PD-1) and may be related to the strong immuno-
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suppression observed in advanced stages of the disease, corresponding to increase in
symptomatology of VL [86].
The role of B cells in CVL is unclear. However, increases in CD21+ B cell, CD4+ T cell, and CD8+
T cell levels are frequently reported, as for the clinical asymptomatic form. Lower frequency
of B cells and monocytes in the bloodstream is an important marker of severe disease, while
increased levels of CD8 + T cells appear to be the most important phenotypic feature for
asymptomatic clinical presentation [74]. Among symptomatic animals, decrease in CD21+ B-
cell count associates with decreased CD4+ T cells, which does not occur with asymptomatic or
disease-free control animals, suggesting that the decay of immunity in leishmaniasis may be
related to decrease in the CD4+ T-cell population [91].
Although the relationship between a pattern of anti-Leishmania humoral response and
resistance or susceptibility to LV is not well defined [92], immunoglobulin profile may appear
as a biomarker for monitoring clinical prognosis and tissue parasitic density, as it is associated
with the progression of clinical signs and increase of parasites in lymphoid organs [73]. Reis
et al. reported increase in IgG1 levels associated with the asymptomatic clinical presentation
and poor tissue parasitic load, while the symptomatic clinical form would be characterized by
high parasitic load and high levels of anti-Leishmania IgG, IgG2, IgM, IgA, and IgE [73, 74].
Teixeira-Neto et al. reported similar results, with symptomatic dogs demonstrating high levels
of anti-Leishmania IgG2 antibodies, whereas the asymptomatic showed higher IgG1 titles, when
compared to IgG2 [93]. Production of IFN-γ is associated with the production of IgG1 [94],
which may indicate a Th1 response profile.
3.2.2. Cytokines and chemokines
Cytokine patterns for CVL have not been well established. Studies are inconclusive, so the
pattern of immune response associated with resistance or susceptibility in infected animals is
yet to be established.
One of the first studies on cytokine profiling in CVL was performed by Pinelli et al. [71], who
observed high levels of IL-2 and tumor necrosis factor alpha (TNF-α) in asymptomatic dogs,
compared with symptomatic ones, which suggests a role of these cytokines in resistance to L.
infantum in dogs naturally or experimentally infected. Since then, much research has been done
in order to elucidate the cytokine profiles found in various tissue compartments of infected
dogs. They revealed contrasting cytokine profiles among different tissues, indicating that the
immune response in LVC occurs in an organ-specific manner [71].
Profile of cytokines in peripheral blood mononuclear cells (PBMC) culture from asymptomatic
dogs experimentally infected with L. infantum shows a predominantly Th1 response, mediated
by expression of IL-2, IFN-γ, and IL-18 and very low IL-4 expression [95]. De Lima [96] dosed
IL-6 and TNF-α in serum of symptomatic dogs naturally infected with L. infantum and
uninfected control dogs. TNF-α was found in similar levels in dogs of both groups, yet IL-6
showed statistically higher levels in dogs with active VL than healthy dogs, thus demonstrating
to be a good indicator for the disease [96].
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After evaluating expression of cytokines in spleen cells from dogs naturally infected with L.
infantum, Lage et al. suggested that CVL is characterized by a mixed response: with production
of cytokines types I and II; involvement of IFN-y and IL-10 and a positive correlation between
IL-10 levels and progression of parasitic load or clinical manifestations of the disease; and
correlation between IFN-γ and increased parasitic intensity of the spleen [84]. In whole blood,
the increase of IL-10 has been associated with detection of parasite DNA [97]. Do Nascimento
et al., in accordance, state that in CVL there is increase in expression of pro-inflammatory
cytokines IFN-γ and TNF-α in dogs with low splenic parasitism, while dogs with higher
parasitic load show an increase in IL-10 [98].
Souza [99] states that asymptomatic dogs have low dermal parasitism and exhibit a mixed
pattern of immune response, with simultaneous increase of type I (IFN-γ and TNF-α) and type
II (IL-5 and IL-13) cytokines, but predominance of type I response. According to the author,
increased and simultaneous expression of IFN-γ and TNF-α in the skin of infected dogs enables
the speculation that these mediators are closely involved with protection mechanisms during
CVL, since these cytokines increased in the skin of animals with the asymptomatic clinical
form. Increased expression of IL-5 and IL-13 in the skin of healthy dogs and negative correla-
tion of the latter with clinical disease progression were also observed. Furthermore, high
simultaneous expression of IFN-γ and IL-13 was found in asymptomatic dogs, indicating the
role of IL-13 in establishing milder clinical forms [99].
Regarding cytokine profile in the bone marrow, Quinnell et al. [94] reported that expression
of mRNA for IL-10, IL-4, and IL-18 was not elevated in infected dogs. However, some infected
dogs had detectable expression of mRNA for IL-4 significantly correlated with more severe
clinical signs. Moreover, expression of mRNA for IL-13 was not detected either in control or
in infected dogs, and unlike in human infection, immunosuppressive activity of IL-10 was not
observed in CVL [94].
Dogs infected with L. infantum exhibit significant decrease in expression of mRNAs for IL-10,
IL-17, TNF-α, IFN-γ, and iNOS in liver tissue. Deficiency in IL-17 mRNA expression was
evident in the symptomatic dogs compared to the asymptomatic. Reduction in cytokine
expression results in decreased iNOS expression and therefore higher parasite load. The
increase in IL-17 expression in the liver of asymptomatic dogs and its correlation with elevated
expression of iNOS indicates a protective role of that cytokine in canine infection by L. infantum
[67]. However, Michelin et al. [100] reported increased TNF-α, IL-4, and IL-10 levels in the liver
of infected dogs compared to healthy dogs. In addition, the association between TNF-α levels
and an increase in parasitic load in the spleen suggests its importance in the evolution of the
infection process [100].
Another subject lacking clarification is the participation of chemokines and their receptors in
resistance or susceptibility to LVC. Knowledge surrounding the role of these modulators in
response to L. infantum infection is critical, considering that the interaction between cytokines
and chemokines may regulate the immune response against the parasite, activating and
recruiting immune cells to areas of infection.
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Menezes-Souza et al. [101] analyzed the expression of CCL2, CCl4, CCL5, CCL13, CCL17,
CCL21, CCL24, and CXCL8 chemokines in the skin of 35 dogs naturally infected by L.
infantum, comparing cutaneous parasitism and clinical manifestations of the disease. Increase
of the parasitic load correlated with increased expression of CCL2, CCL4, CCL5, CCL21, and
CXCL8. On the other hand, CCL24 expression negatively correlated with parasitism [101].
After connecting clinical findings in naturally infected dogs with liver and spleen parasitism
and expression levels for cytokines, chemokines, and their receptors, Albuquerque [67]
showed that symptomatic dogs exhibit low expression of these modulators, alongside lower
inflammatory response, and higher parasite load—primarily in the liver—than asymptomatic
animals. CXCL10 was the only chemokine found at a much higher concentration in both the
liver and the spleen of symptomatic animals. It also positively correlated with clinical score.
The author indicates that expression profiles of hepatic and splenic chemokines and their
receptors are essential for induction of correct cell inflammatory profile, as it has potential to
contain the infection and the disease. Impaired cell migration facilitates replication of the
parasite and development of CVL symptoms [67].
Understanding of the immune response in canine visceral leishmaniasis may reveal the factors
involved with the onset and severity of clinical signs and the damage to host tissues. Addi-
tionally, it takes place as an indispensable tool for development of an effective vaccine.
4. Clinical signs and symptoms
Canine visceral leishmaniasis presents a clinical picture ranging from asymptomatic to
classical symptomatic cases (Figure 4). Infected animals without clinical signs comprise an
Figure 4. Classical symptomatic case with emaciation, thickened skin, cutaneous lesions, exfoliative dermatitis, fur
loss, and cutaneous ulcers.
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alarming 40–80% of all cases, for asymptomatic dogs are a major source of infection for sand
flies, and owners naturally resist to elimination of their animals [102].
At first, kala-azar signals can be rather discrete and easily confused with other diseases.
Animals may have discrete lesions on the edge of the ears and slight changes in blood profile
(mild anemia and/or thrombocytopenia).
Clinical leishmaniasis may appear quickly after infection or within two years. Classic canine
kala-azar is characterized by thickened skin, cutaneous lesions, intermittent fever, appearance
shift and fur loss, periorbital alopecia, hepatosplenomegaly, akinesia, diarrhea, onychogry-
phosis (nail growth; Figure 5), and nosebleeding. Partial paralysis of hindquarters is often seen
in the final stage of the disease.
Figure 5. Onychogryphosis.
The most common skin lesions in dogs with kala-azar are exfoliative dermatitis (generalized,
regional, or localized); ulcerative dermatitis, onychogryphosis, and papular dermatitis.
Cutaneous ulcers are usually located on the ear margins and have been attributed to local
trauma and/or vasculitis, pressure points (Figure 6), limbs, and mucocutaneous junctions.
Focal or multifocal nodular forms have a high amastigote load and may indicate either
inefficient or strong cellular immunity by the host [101, 103–105].
Ocular disease occurs in CVL, with anterior uveitis being the most common ocular manifes-
tation, characterized by conjunctivitis, blepharitis, periocular alopecia, exophthalmia, keratitis,
keratoconjunctivitis sicca, anterior uveitis, glaucoma, and retinal detachment [106].
The nosebleeding (epistaxis) occurs due to thrombocytopenia and is often confused with
ehrlichiosis, a bacterial disease transmitted by ticks, which in many cases might associate with
leishmaniasis. In endemic areas, it is advisable that any diagnosis of ehrlichia or anaplasma in
dogs must be accompanied by differential diagnosis of kala-azar.
In general, dogs in endemic areas are poly-infected and malnourished, particularly stray dogs
or those who frequently wander on the streets, leading to a plurality of overlapping clinical
pictures. Among other conditions, furfuraceous flaking due to scabies, weight loss as
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consequence of other infections or lymphomas, and autoimmune diseases, such as systemic
lupus erythematosus, often confuse diagnosis since clinical signs are usually not pathogno-
monic. Therefore, differential diagnosis must be a concern for the small animal clinician [107,
108].
Figure 6. Cutaneous ulcer located on a pressure point.
5. Treatment
Treating seropositive dogs for canine visceral leishmaniasis (CVL) is a controversial practice
in Brazil and, above all, not recommended by the World Health Organization, mainly because
it does not lessen the importance of the dog as a reservoir, and utilizes drugs used in human
treatment of visceral leishmaniasis (VL) [109]. Nevertheless, European countries legally
established treatment since the twentieth century [110].
Frequent usage of these drugs in veterinary clinics may select resistant parasites due to
variation in sensitivity of leishmania species, in addition to providing low parasiticide effect,
thus interfering negatively in human treatment [111]. The lack of success for parasitological
cure occurs mainly because it is an intracellular parasite and is located in less vascularized
tissues where it can be difficult to obtain therapeutic doses, such as the vitreous body [112].
Many studies have been conducted in order to find an effective treatment for CVL, but drugs
currently available are still inefficient, only allowing temporary remission of clinical signs.
Besides, some have a high cost and produce toxic effects. Pentavalent antimonies (glucamine
antimoniate—Glucantime® or sodium stibogluconate—Pentostam®) are widely used in CVL
therapy protocols because they usually produce faster clinical remission but are often com-
bined with allopurinol, since they do not prevent relapses [34]. A variety of drugs, such as
amphotericin B, pentamidine isethionate, ketoconazole, fluconazole, miconazole, itraconazole,
has been used either isolated or in combination and produced different results [111].
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5.1. Chemotherapy
Due to the possibility of parasitic resistance to first-choice drugs, chemotherapeutic treatment
options are limited. In addition, due to the high cost and long-term use, chemotherapy becomes
an undesirable option for owners.
In veterinary medicine, the first choice as chemotherapy for treatment of CVL is allopurinol,
a leishmaniostatic drug that acts by inhibiting leishmania growth through DNA modification.
It has low cost, but parasite resistance to it remains unknown. Allopurinol is however the only
drug recommended by the World Health Organization, especially since it is little used for
treatment of human leishmaniasis [113].
Antimonials are leishmanicidal drugs that hinder promastigote metabolism by inhibiting
glycolytic activity. These are drugs of choice for human treatment of VL but are chemically
similar to those that have been used in therapeutic protocols in dogs. Their toxicity and efficacy
are related to the antimony content [113].
When assessing the therapeutic efficacy of Glucantime alone or associated with an antigenic
extract of L. braziliensis in experimentally infected asymptomatic dogs, reduction in parasite
burden and antibody levels decreased, but actual cure was not achieved. Yet, upon using
meglumine antimoniate and allopurinol—alone and in combination—in dogs naturally
infected by L. infantum, symptomatic animals showed remission of clinical signs about 60 days
after the treatment, accompanied by restoring of normal urinary and hematologic profiles.
Despite clinical improvement of treated animals, however, the combination was not able to
eliminate the parasite in all dogs. Thus, this protocol is not recommended, since treated dogs
would go on as a source of infection for humans and other dogs, similar to results obtained
using antimoniate, which promoted hematologic normalization and bone marrow recovery,
but not parasitological cure, and to findings from another study wherein dogs showed
increased parasitic load in lymph nodes [114–117].
In accordance with Ikeda-Garcia et al. [116], Manna et al. [118] monitored leishmania DNA
load in infected dogs through real-time PCR, using a similar treatment protocol. Therapy
resulted in clinical improvement accompanied by reduction in parasite burden, but even after
a long period of treatment with allopurinol alone, parasites remained in tissues [116, 118].
Miltefosine is another drug used in human treatment that has been evaluated for canine
treatment in recent years. It is a phospholipid antibiotic of broad spectrum with leishmanicide
effect that improves the activation of both macrophages and T cells [119]. After evaluating
efficacy of three treatment protocols for dogs naturally infected with L. infantum, significant
clinical improvement was observed and later progressed to full recovery and humoral
stimulation, but did not assure cure, on the contrary, progressively increased parasite load.
Hence, miltefosine alone is not recommended for treatment. The study also investigated the
profile of major cytokines involved in CVL healing process, and findings showed an increase
of IFN-γ within 90 days after treatment, when the parasite load in bone marrow aspirates also
decreased. There was a decrease of IL-4, indicating possible resolution of the infection and
efficacy of the treatment, since this cytokine is a good marker for the occurrence of active
disease [112, 120].
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Some studies seek to associate chemotherapeutic treatment to immunomodulatory drugs,
which plays a role in therapeutic protocols by controlling clinical signs and in prevention
protocols by enhancing the immune cell-mediated response through activation of macrophag-
es via helper T cells, in order to destroy phagocytized microorganisms. Domperidone is a
receptor antagonist of dopamine D2 that has been used as well. When orally given to naturally
infected dogs, results showed a reduction of clinical signs and titers of anti-leishmania
antibodies [121]. In Spain, Sabaté et al. [122] used a treatment protocol with domperidone in
seronegative dogs in an area with high prevalence of L. infantum and later exposed the animals
to the vector. After 21 days of treatment, the treated group had lower antibody titer, confirming
that implementation of treatment with this drug reduces the risk of developing CVL [122].
Nevertheless, further clinical trials are needed to determine the optimal dose, as well as
posttreatment investigations to check for parasitological cure, since the drug is a good choice
for infected animals with kidney failure due to its route of administration, and it is a low-cost
option [121].
Amphotericin B is a broad-spectrum macrolide antibiotic produced by actinomycete Strepto‐
myces nodosus [123], available for usage in VL treatment. It has a powerful leishmanicide effect
and works by binding to esters on the parasite’s plasma membrane [111]. According to Solano-
Gallego et al., this drug has disadvantages concerning its route of administration (IV) and its
nephrotoxic potential; however, its use results in less failures and recurrences [34]. Addition-
ally, it is frequently used in the treatment of both human and canine VL for being inexpensive.
Athanasiou et al. [124] investigated the effectiveness of aminosidine sulfate, a leishmanicide
antibiotic of the aminoglycoside class, in the treatment of dogs naturally infected. They
observed reduction in clinical signs and parasite density, in antibody titers through indirect
immunofluorescence, and in prevalence of positive dogs using PCR 3 months after the end of
the experiment. These findings can be explained by direct action of the drug as well as
activation of cellular immunity. However, more studies are required to prove its therapeutic
efficacy for CVL, especially considering its affordable price to owners and market availability
[124].
Despite the research on efficacy of different classes of medications for CVL treatment, no great
progress has been done regarding toxicity or parasitological cure, highlighting the necessity
for evaluation of new formulations and medicaments to be used exclusively for treatment of
CVL.
5.2. Immunochemotherapy
Immunotherapy can be an effective addition to chemotherapy, as it induces effector immune
response faster than the isolated use of chemotherapeutic drugs [125]. In a trial, the combina-
tion of N-methyl meglumine antimoniate (Glucantime®) and lyophilized recombinant vaccine
Leish-110f®, together with adjuvant monophosphoryl lipid A plus (MPL-SE®) to treat symp-
tomatic animals naturally infected with L. infantum, was effective in reducing parasitic load.
This combination enables reduction of chemotherapy doses, consequently lowering the risks
of toxicity and death. However, the use of multiple recombinant antigens could provide better
results [126].
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Borja-Cabréra et al. [127] evaluated the efficacy of immunotherapeutic vaccine Leishmune®
administered alone, both in commercial formulation enriched with saponin and in laboratory
formulation, compared to its use in combination with amphotericin B and allopurinol, in dogs
naturally infected with L. infantum, but found no significant differences between the vaccine
formulations tested. As for the type of treatment, the group submitted to immunochemother-
apy with saponin-enriched Leishmune® vaccine abolished, not only the symptoms but also the
latent infection condition, curing the dogs [127].
Joshi et al. [128] used Balb/c mice in order to verify in vivo therapeutic potential of the first
generation of vaccines with dead L. donovani antigen (KDL) combined with adjuvant (MPL-A)
and leishmanicidal chemotherapy such as cisplatin and sodium stibogluconate (SSG) and then
compared those to isolated chemotherapy and immunotherapy. In animals treated with
vaccine associated to SSG, there was a 98.50% reduction in serum parasitic levels, but the study
also noted that the use of any of the chemotherapeutic associated with vaccination resulted in
direct parasite elimination by drug activity and activation of the immune cell-mediated
response. They concluded that immunochemotherapy protocols may be effective, but further
studies are needed in different animal models in order to better understand the immune
response [128].
5.3. Immunotherapy
Immunotherapy is often considered for CVL prevention and control as a preferable alternative
to euthanasia, due to the absence of a low-toxicity chemotherapy treatment and increasing
resistance. According to Grandoni [129], vaccines are regarded as the best tool for eradication
of the disease, particularly because it reduces the incidence of new cases, considering that the
immune system fails to efficiently control the infection as it mediates a weak protective cell
response. This relates to a dichotomy between the trigger of a Th1 response related to resistance
and a Th2 response associated with susceptibility to infection, increased parasitic load, and
strong but ineffective humoral immune response [129].
According to Joshi et al., an effective vaccine must induce a strong and long-lasting Th1
response as to prevent the initial establishment of infection: by definition, a prophylactic
vaccine [128]. However, when it comes to a disease caused by an obligate intracellular
protozoan, the aim is to at least control progression to severe disease and prevent transmission
from host to vector, hindering maintenance of the epidemiological cycle.
So far, vaccines formulated for CVL include dead parasites, protein components or parasite
subunits, purified cell fractions, vector salivary recombinant proteins, and viral particles that
encode parasite’s virulence factors and plasmid DNA [130]. Leishmune® (Zoetis Animal
Health) was the first vaccine approved for commercial use in Brazil, in 2003. However, in 2014
the Ministry of Agriculture, Livestock, and Supply (MALS) halted manufacturing and
marketing licenses due to problems in phase III. It consists of a glycoprotein antigen that binds
recombinant fucose mannose which was able to stimulate good cellular immune response,
decreasing IL-4, and activate CD4+ T cells, producing TNF-α and IFN-γ, important cytokines
in resistance [131, 132]. Accordingly, a study done by Borja-Cabrera et al. found that the vaccine
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induced a long-lasting protective effect of humoral and cellular immunity, along with disap-
pearance of clinical signs and parasitemia [133].
Leish-Tec® (Hertape), a vaccine comprising recombinant protein A2 as antigen in adjuvant
saponin QuilA, continues to be marketed in Brazil since 2008, when it was recorded by the
MALS. It has been demonstrated to offer partial protection against L. infantum in Beagle dogs,
producing good humoral and cellular immune responses, high levels of anti-protein A2 IgG
and IgG2, and IFN-γ [134, 135].
Despite increasing progress in production of vaccines against CVL in Brazil and worldwide,
there is much to be improved regarding the induction of durable and efficient cellular and
humoral immune response. Moreover, new affordable vaccines ought to be produced for the
population, since those available in the market so far are expensive and not viable for use in
public health.
6. Diagnosis
The clinical diagnosis of CVL is challenging, as signs are usually not specific for the disease;
laboratory assays are therefore of paramount importance. Moreover, as the dog is considered
to be the major reservoir in Brazil, serological assays constitute the basis to identify infected
dogs and to direct public health actions aiming the disease control.
The indirect immunofluorescence antibody test (IFAT) was established as the standard
serodiagnosis in public health programs more than 40 years ago. It was later substituted by an
ELISA based on crude leishmania antigens [111] and more recently by a recombinant ELISA
and an immunochromatographic rapid test for detecting K26/K39-reactive antibodies in canine
sera [136, 137]. According to the recommendation from the Brazilian Ministry of Health, sera
collected from dogs in seroepidemiologic surveys as part of the Leishmaniasis Control
Program are first screened using the fast immunochromatographic assay (known as dual-path
platform (DPP)), and the positive samples are retested in the recombinant ELISA. The approach
undoubtedly speeds up the screening [138], but due to the DPP low sensitivity in cases of sera
from asymptomatic dogs [137, 139, 140], a sizable set of infected dogs possibly remains in the
endemic areas, jeopardizing the effectiveness of control actions.
Private laboratories used to rely in a single result obtained by the use of a commercial re-
combinant ELISA kit (ELISA S7) registered at the Brazilian Ministry of Agriculture, Livestock,
and Supply for the diagnosis of CVL (www.biogene.ind.br). More recently, some fast immu-
nochromatographic assays started to be used, such as the Alere assay [141], but high costs
preclude their adoption in the routine diagnosis. A recombinant K39-based ELISA developed
for research use only (http://www.inbios.com/kalazar-detect-elisa-system-for-visceral-
leishmaniasis-intl/) has also seen some use in routine commercial CVL diagnosis.
The official recombinant ELISA assay and the ELISA S7 have similar sensitivity and specific-
ity indexes and perform equally well in the identification of seropositive, supposedly infect-
ed dogs. They also do not display significant rates of positive reactions in cases of
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vaccinated dogs. Other serological assays, e.g., the direct agglutination (DAT), are not easily
available in Brazil and were never adopted in private or public labs. Although new antigens
have been described in the last years (e.g., [142]), their commercial use in serodiagnosis is
still uncertain. Although available as commercial kits (http://www.genesig.com/products/
9332?gclid=CNXfgtXc_c4CFcoHkQodMm4Ctw), PCR assays are seldom used and have lim-
ited application for the routine diagnosis.
As the existing recombinant ELISA assays have high sensitivity and specificity even in the
serodiagnosis of CVL in asymptomatic dogs, one could argue against the need of new
laboratory tests. However, claims of cross reactions with babesiosis and other common canine
infectious diseases [138] continue to stir dissatisfaction.
In conclusion, no diagnostic breakthroughs have been described and no innovative technology
was introduced in the market in the last years, and there are no evidences that this scenario
will be changed in the near future.
7. Epidemiological surveillance, preventive, and control measures
Visceral leishmaniasis control activities focus on reducing morbidity and mortality through
early diagnosis and treatment of human cases, monitoring and euthanasia of seropositive dogs
and sand fly population control via entomological surveillance such as chemical control.
Additionally, they include education and health activities that involve joint actions aiming to
improve population’s quality of life, such as provision of basic sanitation and proper trash
disposal [143].
In Brazil, the Visceral Leishmaniasis Control Program (VLCP) recommends surveillance,
preventive and control measures of human and canine visceral leishmaniasis [11]. Epidemio-
logical surveillance aims to reduce mortality and morbidity rates through early diagnosis and
treatment of human cases and to reduce the risk of transmission by controlling reservoirs and
vector populations. Surveillance comprises entomological surveillance of human and canine
cases. What is set at national level for epidemiological surveillance of VL, emphasizing canine
population, is described in the following paragraphs.
Through epidemiological analysis of VL in the state or municipality, transmission areas are
classified in areas with VL cases or silent areas (without cases). Areas with cases are those with
record of a first confirmed case, those with sporadic, moderate, and intense transmission and
those undergoing outbreaks. Silent areas or areas without cases are classified as vulnerable
(receptive and unreceptive) or not vulnerable.
Entomological surveillance aims to gather quantitative and qualitative information about L.
longipalpis and/or L. cruzi vectors. This is a task for the state and/or municipal health depart-
ments, which must work integratedly in order to optimize resources and effectiveness of sand
fly control activities.
In regard to dogs, surveillance focuses on suspect canine cases (symptomatic animals in
endemic or outbreak areas) and on those confirmed by (a) laboratory criteria, symptomatic
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and positive in serological and/or parasitological test; (b) clinical and epidemiological criteria,
symptomatic from endemic or outbreak areas without diagnostic confirmation; and (c) infected
dogs, asymptomatic and positive in serological and/or parasitological test. When a canine case
is identified, delimitation of the area to be investigated is among the surveillance actions to be
taken. In those areas, active search for symptomatic dogs must be carried out for parasitological
examination, and if the agent is found, serological survey of all animals in the area must be
done in order to evaluate local prevalence and to implement appropriate measurements.
Sample and census serosurveys must be performed as monitoring activity. The sample
serological survey must be carried out in silent and receptive municipalities with L. Longipalpis
and in those with moderate and intense transmission. The census serological survey must be
performed in urban areas of silent and receptive municipalities with canine population smaller
than 500 animals, in urban areas of moderate or intense transmission and rural areas in any
transmission situation. The aim of a census survey is to control disease by identification of
infected dogs in order to perform euthanasia and assess prevalence. It must be performed
annually for at least three consecutive years, even without notification of new confirmed
human cases.
Preventive measures regarding canine population are (a) control of errant canine population,
(b) donation of dogs after performing negative serological tests, (c) vaccination against CVL,
(d) the use of fine mesh screen at individual or collective kennels, and (e) the use of collars
impregnated with deltamethrin 4%.
Canine reservoir control measures consist in euthanasia of seropositive dogs and/or positive
in parasitological tests, besides disposal of the bodies in accordance with the provisions of
RDC Resolution No. 33, of February 25, 2003, from the National Agency for Health Surveil-
lance.
In Brazil, since 2000, as part of the decentralization process undergone by the National Health
Foundation (FUNASA), the states’ federal district and municipalities became responsible for
operating assistance, epidemiology, and disease control activities. They now receive almost all
movable property, allocated in all federal units and more than 26,000 servers, and resources
for maintenance of the transferred responsibilities [144]. However, despite the decentralization
and recommendations by VLCP, the action taken toward canine reservoirs have been mainly
restricted to areas of human case occurrences, that is, after a human case confirmation, canine
serological survey follows in the surrounding area, and later, euthanasia of animals found
seropositive in screening (DPP®) and confirmatory (EIE-Biomanguinhos) tests. Individual
preventive measures such as vaccination, coverage of kennel doors and windows with mesh
screen, and collars impregnated with deltamethrin 4% are restricted to animals whose owners
have relatively high economic standard.
Several factors hinder the fulfillment of activities imposed by VLCP. Some of them are the lack
of federal funding; insufficient staff to perform activities related to VL and other endemic
diseases; prioritization for control of other endemic diseases such as dengue, Zika, and
chikungunya; expansion of transmission areas; and interference of veterinarians, animal
owners; and nongovernmental organizations (NGOs) regarding euthanasia of reservoirs, as
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such procedure generates controversy regarding its control efficacy, although recommended
in Brazil [145].
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